Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KEYNOTE-B10: Pembrolizumab + Carboplatin + Paclitaxel in R/M HNSCC
NCT04489888Phase 4Completed
- Sponsor
- Merck & Co.
- Start
- Oct 2020
- Primary completion
- Feb 2023
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 5
01
Overview
A Phase 4 trial of pembrolizumab in head and neck squamous cell carcinoma (HNSCC), sponsored by Merck & Co.. Started Oct 2020; status: completed.
02
Drugs
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT04489888.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04489888.